CytoVia Therapeutics, Inc. is a private, clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel gene therapies to address rare neurological diseases with high unmet medical need. The company leverages adeno-associated virus (AAV)-based gene delivery technology to target the underlying genetic cause of these disorders. Their lead program, CYTO-101, is being developed for Friedreich's Ataxia (FA) and has entered Phase 1/2 clinical trials. CytoVia aims to make a meaningful difference in the lives of patients and families affected by these devastating conditions.
The headquarters serves as the central hub for research and development, clinical operations, strategic planning, and corporate administration, driving the advancement of their gene therapy pipeline.
Situated in the vibrant Avalon complex, the office likely provides modern facilities. While specific internal features are not publicly detailed, it is presumed to include specialized laboratory space conducive to gene therapy research and development alongside corporate offices.
As a clinical-stage biotechnology company, the culture is likely highly collaborative, science-driven, innovative, and patient-focused. It's expected to be a dynamic and fast-paced environment dedicated to advancing cutting-edge therapies.
The Alpharetta location places CytoVia Therapeutics within the growing Atlanta metropolitan area's biotechnology cluster, offering access to a skilled talent pool, research institutions, and a supportive business environment. Avalon's amenities also contribute to a positive work environment.
CytoVia Therapeutics is currently focused on its research, development, and clinical trial activities, primarily managed from its U.S. headquarters in Alpharetta, GA. While its therapeutic ambitions are global, especially for rare diseases affecting diverse populations, its direct operational footprint is concentrated in the United States. Global engagement is primarily through clinical trial sites, potential collaborations with international research institutions, and future partnerships for drug development and commercialization.
8000 Avalon Boulevard, Suite 202
Alpharetta
GA
USA
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Cytovia Therapeutics' leadership includes:
Cytovia Therapeutics has been backed by several prominent investors over the years, including:
In April 2023, CytoVia Therapeutics significantly strengthened its leadership team with the appointment of Dr. Philippe M. Bishop as Chief Medical Officer. No other major executive hires or departures have been publicly announced in the immediate last 12 months.
Discover the tools Cytovia Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
CytoVia Therapeutics's primary public contact email is info@cytoviatherapeutics.com. For direct communication with employees, a common professional format is likely used, such as combining the first initial and last name.
[first_initial][last]@cytoviatherapeutics.com
Format
jdoe@cytoviatherapeutics.com
Example
70%
Success rate
CytoVia Therapeutics Website • March 7, 2024
CytoVia Therapeutics announced the dosing of the first patient in its Phase 1/2 clinical trial evaluating CYTO-101, an AAV-based gene therapy candidate for the treatment of Friedreich’s Ataxia....more
CytoVia Therapeutics Website • October 18, 2023
The U.S. FDA cleared the Investigational New Drug (IND) application for CYTO-101 and granted Orphan Drug Designation for the treatment of Friedreich’s Ataxia....more
CytoVia Therapeutics Website • April 17, 2023
Dr. Philippe M. Bishop was appointed as Chief Medical Officer, bringing significant experience in orphan drug development and clinical expertise to the company's leadership team....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Cytovia Therapeutics, are just a search away.